Interferons
Lupus Erythematosus, Systemic

Anifrolumab

Anifrolumab is an investigational agent designed to address the complex challenges associated with systemic lupus erythematosus (SLE). This humanized IgG1k monoclonal antibody is 1 of 3 anti-type-1 interferon agents scrutinized for their potential in treating SLE. In initial in vivo studies revealing elevated serum interferon (IFN) levels in autoimmune disease patients, compared to healthy counterparts, anifrolumab functions by inhibiting cellular signaling mediated by the type-1 interferon receptor (IFNAR1) upon activation. This comprehensive activity will unravel the drug’s therapeutic indications, mechanism of action, pharmacokinetics, potential adverse events, and contraindications, providing an in-depth understanding of its role in SLE therapy. Learners gain insights into the interprofessional clinical approach essential for effectively treating SLE, enhancing their ability to navigate the nuanced landscape of anifrolumab’s application in clinical practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.